Treatment of patients with rheumatoid arthritis (RA) with non-tumor necrosis factor inhibitor (TNFi) biologic disease-modifying antirheumatic drugs (bDMARDs) may not pose an increased risk for cancer, ...

Still's disease is an unusual form of arthritis that, in children, is also called systemic juvenile idiopathic arthritis, but it can also develop in adults. Few rigorous studies have examined biologic ...

Janus kinase (JAK) inhibitors had a marginally superior effect on pain relief when compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA), particularly when ...

Patients with psoriatic arthritis who received bDMARDs vs cDMARDs had a lower risk for major adverse cardiovascular events, all-cause mortality, and cardiovascular mortality. Biologic ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Disparities in the use of biologic and targeted synthetic disease-modifying antirheumatic drugs for ...

Advances in biotechnology, a greater understanding of the immunopathogenesis of rheumatoid arthritis (RA) and a desire for more effective therapeutics have led to the development of a class of ...

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints (those between the spine and hipbone). Less commonly, AS can affect other joints such ...